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Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related
cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist
in discovery of mechanisms and prediction of risk.
Methods
We conducted a multi-centre case-control study (GenomALC) comparing 1293 cases
(with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol
exposure but no evidence of liver disease, 73.6% male). Information confirming or
excluding cirrhosis, and on alcohol intake and other potential risk factors, was obtained
from clinical records and by interview. Case-control differences in risk factors
discovered in the GenomALC participants were validated using similar data from 407
cases and 6573 controls from UK Biobank.
Results
The GenomALC case and control groups reported similar lifetime alcohol intake (1374
versus 1412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1288) versus
6.5% (48/734), p = 2.27 x 10  -18  ) and higher pre-morbid BMI (26.37 ± 0.16 kg/m  2  )
than controls (24.44 ± 0.18 kg/m  2  , p = 5.77 x 10  -15  ). Controls were significantly
more likely to have been wine drinkers, coffee drinkers, smokers and cannabis users
than cases. Cases reported a higher proportion of parents who died from liver disease
than controls (OR 2.25 95% CI 1.55 to 3.26). Data from UK Biobank confirmed these
findings for diabetes, BMI, proportion of alcohol as wine and coffee consumption.
Conclusions
If these relationships are causal, measures such as weight loss, intensive treatment of
diabetes or pre-diabetic states, and coffee consumption should reduce risk of alcohol-
related cirrhosis.
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Study Highlights 
What is known: 
 Lifetime alcohol exposure reported by patients with alcohol-related cirrhosis varies 
widely, and only some high-risk drinkers develop cirrhosis 
What is new here:  
 Susceptibility to cirrhosis among high-risk drinkers is affected by family history of 
alcohol-related liver disease 
 Effects of obesity, diabetes, coffee consumption and beverage preference have been 
confirmed in data from two independent studies and this information should help in 
preventing or delaying cirrhosis in patients whose drinking places them at risk. 
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ABSTRACT 
Background: Sustained high alcohol intake is necessary but not sufficient to produce 
alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, 
would assist in discovery of mechanisms and prediction of risk.  
Methods: We conducted a multi-centre case-control study (GenomALC) comparing 1293 
cases (with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol 
exposure but no evidence of liver disease, 73.6% male). Information confirming or excluding 
cirrhosis, and on alcohol intake and other potential risk factors, was obtained from clinical 
records and by interview. Case-control differences in risk factors discovered in the 
GenomALC participants were validated using similar data from 407 cases and 6573 controls 
from UK Biobank. 
Results: The GenomALC case and control groups reported similar lifetime alcohol intake 
(1374 versus 1412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1288) versus 
6.5% (48/734), p = 2.27 x 10-18) and higher pre-morbid BMI (26.37 ± 0.16 kg/m2) than 
controls (24.44 ± 0.18 kg/m2, p = 5.77 x 10-15). Controls were significantly more likely to 
have been wine drinkers, coffee drinkers, smokers and cannabis users than cases. Cases 
reported a higher proportion of parents who died from liver disease than controls (OR 2.25 
95% CI 1.55 to 3.26). Data from UK Biobank confirmed these findings for diabetes, BMI, 
proportion of alcohol as wine and coffee consumption.  
Conclusions: If these relationships are causal, measures such as weight loss, intensive 
treatment of diabetes or pre-diabetic states, and coffee consumption should reduce risk of 
alcohol-related cirrhosis.  
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Sustained high alcohol intake, often associated with alcohol dependence, can lead to alcohol-
related liver diseases including cirrhosis. The usual progression is through fatty liver, 
frequent in high-risk drinkers but reversible with abstinence, to fibrosis and cirrhosis. Some 
patients will develop alcoholic hepatitis, and some will develop hepatocellular carcinoma 
(HCC), generally with cirrhosis as a precursor. Therefore, cirrhosis is not only the end-stage 
of liver damage, but also increases risk for other life-threatening conditions. Apart from 
abstinence from alcohol, supportive measures, and liver transplantation in selected abstinent 
patients, current treatment options for alcohol-related cirrhosis are limited. 
The relationship between alcohol intake and cirrhosis has been recognised since the late 
eighteenth century (1), with subsequent efforts to quantify this association made by 
Pequignot (2) who noted an increased risk of cirrhosis in people drinking more than 40 grams 
of alcohol per day. It is known that women are more susceptible to liver damage from alcohol 
than men (3), and larger studies and meta-analyses (4) have refined the threshold for 
detectable risk from alcohol intake.  
It is notable that only a minority of high-risk drinkers develop cirrhosis. It is difficult to find 
reliable estimates, but in Denmark 7.7% of patients diagnosed with harmful alcohol use and 
8.8% of those diagnosed with alcohol dependence developed cirrhosis over the subsequent 15 
years (5). Meta-analysis (6) showed that 7-16% of people in alcohol problem cohorts had 
cirrhosis after 8-12 years. Variation in susceptibility may be due to genetic variation, and/or 
presence of other environmental and lifestyle risk factors which increase the probability of 
liver damage. Apart from alcohol intake and gender, obesity (also associated with non-
alcoholic liver disease) has the strongest evidence for increasing risk of alcohol-related 
cirrhosis. For instance, liver biopsy histology showed more severe abnormalities in patients 
with alcohol use disorders with greater body weight (7); this was confirmed in a subsequent 
study (8) which showed that being overweight was a risk factor for steatosis, hepatitis and 
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cirrhosis in addition to the effects of age, gender and duration of alcohol abuse. Other studies 
have also found an association between obesity or body mass index (BMI) and liver disease 
(9, 10), fibrosis (11), alcoholic hepatitis (12) or HCC (13). There is evidence that coffee or 
tea consumption can reduce risk of liver disease or favourably affect biomarkers associated 
with liver disease (14-17). Smoking has been associated with increased risk of alcohol-related 
cirrhosis and of cirrhosis in general, particularly among women (18). A recent report showed 
that cannabis use protected against liver disease in patients with alcohol use disorders (19), 
possibly through effects on inflammation mediated by cannabinoid receptors (20).  
There is a lack of hard data from twin or family studies on genetic risk for alcohol-related 
cirrhosis. Alcohol dependence is partially heritable (21) but twin studies on its consequences 
such as alcohol-related liver disease (22) have been limited by small numbers and lack of 
adjustment for heritable effects on alcohol exposure (23). Our earlier report (24) suggested 
that a history of liver disease in a parent with alcohol problems was associated with increased 
risk of alcohol-related cirrhosis. The known genetic risk loci for cirrhosis in PNPLA3 and 
HSD17B13 (25, 26) are associated with lipid metabolism and potentially with metabolic 
changes which accompany obesity. 
The GenomALC Consortium (24) was initiated to gather data and samples for identification 
of risk factors for alcohol-related cirrhosis, including a case-control genetic association study. 
In this paper we focus on comparison of case and control groups for potential clinical and 
phenotype factors that alter disease risk including beverage preference, other substance use, 
family history, obesity and diabetes. Where we have identified potential risk-altering factors 
from our data, we have attempted validation using comparable data from the UK Biobank. 
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SUBJECTS AND METHODS 
GenomALC Study 
Recruitment and data collection were based on our published GenomALC protocol (24). Two 
groups of patients were recruited between 2012 and 2017 in six countries (Australia, France, 
Germany, Switzerland, UK and USA).. Cases were recruited through hepatology clinics and 
controls were recruited from psychiatric clinics or detoxification facilities. All participants 
gave written informed consent. The study was approved by appropriate Ethics Committees or 
Institutional Review Board at each site and conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. Data and samples were identified by a study-specific code with no 
personal information. 
To be confident that participants either had or were at substantial risk of alcohol-related 
cirrhosis and to minimise the chance that cirrhosis was caused by factors other than alcohol, 
we recruited patients with alcohol intake of at least 80 grams per day for men and 50 grams 
per day for women for 10 years or more. Both cases and controls were required to have 
negative test results (antibody/antigen/viral load) for hepatitis B and C, and no clinical or 
serological evidence of human immunodeficiency virus (HIV). Unequivocal evidence of 
cirrhosis in cases was defined as imaging results (sonography, computed tomography, 
magnetic resonance imaging) compatible with cirrhosis; together with detectable ascites by 
imaging or paracentesis, and/or grade 2 or higher spontaneous hepatic encephalopathy, and/or 
moderate or large oesophageal varices on upper gastrointestinal endoscopy. Histological 
cirrhosis on biopsy was defined as Metavir fibrosis stage F4 or Ishak fibrosis stage 5 or 6. 
Liver stiffness (Fibroscan®) was accepted as diagnostic for cirrhosis if greater than 22 kPa in 
the presence of aspartate aminotransferase (AST) less than 100 u/l or ≥30 kPa if AST 
between 100-200 IU/L (27, 28) . Other causes of liver disease, including haemochromatosis, 
Wilson’s Disease, and autoimmune liver disease were excluded by laboratory tests or clinical 
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criteria, and any patient who had received a liver transplant for a condition other than 
alcohol-related cirrhosis was also excluded. Controls met the alcohol intake criteria but with 
no evidence or history of liver disease, had normal results for liver function tests (AST, 
alanine aminotransferase (ALT), bilirubin, albumin, but not necessarily for gammaglutamyl 
transferase (GGT)), platelet count and International Normalised Ratio (INR), and/or had less 
than 6 kPa liver stiffness (Fibroscan®), while drinking or within seven days of abstinence. 
Information was collected on demographics, self-reported ancestry, history of alcohol, 
tobacco and cannabis use, tea and coffee consumption, clinical symptoms, biopsy results if 
available, and biochemical and haematological test results. The data collection form (24) is 
available from the corresponding authors. Data were transferred to a central site, checked for 
anomalies and if necessary corrected after clarification, and stored in a secure password-
protected system.  
Analysis of familial transmission of risk for alcohol-related cirrhosis was based on 
participants’ responses to questions about their parents: 
a. Did your father have problems with alcohol?           
b. If YES, did he die of liver disease?       
c. Did your mother have problems with alcohol?        
d. If YES, did she die of liver disease? 
This analysis was restricted to patients whose fathers or mothers were reported to have had 
‘problems with alcohol’, and assumes that death from liver disease in a parent with alcohol 
problems is due to alcohol-related liver disease (potentially alcoholic hepatitis or HCC, as 
well as alcohol-related cirrhosis). 
UK Biobank 
Data from the UK Biobank (https://www.ukbiobank.ac.uk/, accessed 2018-11-07) on a 
population cohort of 502,616 participants from the UK were made available under approval 
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number 18870. Baseline assessment included a demographic, lifestyle and health 
questionnaire and participants agreed to have their health records accessed for baseline and 
follow-up outcomes (29). Participants had given informed consent as described at 
http://www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Consent_form.pdf and ethical 
approval was given under the UK Biobank Ethics and Governance framework 
(https://egcukbiobank.org.uk/). 
For this analysis we extracted information on people who  
(1) reported alcohol intake of ≥80 grams/day for men or ≥50 grams/day for women at the 
time of assessment, with self-reported similar or greater alcohol intake ten years 
previously, and no reported alcohol-related cirrhosis or other alcohol-related liver 
disease (controls, N = 6573); or  
(2) had a diagnosis of alcohol-related cirrhosis (ICD10 code K70.3) (cases, N = 407).  
Relevant information on these UK Biobank participants included age, sex, calculated BMI, 
waist/hip ratio (WHR), self-reported current alcohol intake, daily tea and coffee consumption, 
smoking status (never, former or current smoker), cannabis use (ever), and diabetes status 
(self-reported in response to the touchscreen question ‘Has a doctor ever told you that you 
have diabetes?’ and if Yes, confirmed by interview).  
Data analysis 
Data analyses used SPSS Version 22 (IBM Corp., 590 Madison Avenue New York, NY 
10022). Alpha (p-value) <0.05 and Odds Ratio (OR) when 95% Confidence Interval (CI) 
excluded 1.00 were considered significant. Statistical tests for differences between case and 
control groups were based on contingency tests for categorical variables, and ANOVA for 
quantitative variables. Logistic regression analysis to evaluate independent predictors was 
based on stepwise entry until all significant (p < 0.05) variables had been entered. For 
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evaluation of the effects of family history, the possibility of differential transmission of 
effects to male and female patients was taken into account using patient sex for stratification, 
testing for heterogeneity of OR across strata with the Breslow-Day test and, if no 
heterogeneity was found, estimating the common OR. Similarly, for testing whether case-
control differences were consistent across country of recruitment, countries were treated as 
the strata and heterogeneity and common odds ratios were evaluated. 
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RESULTS 
GenomALC participants – case-control comparisons 
1293 cases and 754 controls were recruited between 2012 and 2017. There were 978 male 
and 315 female cases, and 555 male and 199 female controls. Clinical features of the cases 
are summarised in Supplementary Table 1. Most participants reported only ‘European’ 
ancestry, with the highest proportion in Germany (99%) and lowest in the US (88%).  
Cases drank significantly less alcohol per day than controls, but had been drinking for 
significantly longer. Total lifetime alcohol intake did not differ significantly between male 
cases and controls, and in female cases was slightly lower than for controls (Table 1). A 
breakdown by country of recruitment is given in Supplementary Table 2, with comparisons of 
lifetime alcohol intake in cases and controls by country in Supplementary Figure 1. Controls 
reported taking a significantly higher proportion of their total alcohol in the form of wine 
(Table 2), but were less likely to report usually drinking with (rather than between) meals.  
Forty eight percent of cases but only 28% of controls were currently living with a spouse or 
partner. There was no significant difference in years of education. Controls were more likely 
than cases to have been coffee drinkers during the time they were drinking alcohol heavily, 
and to have drunk more coffee per day, but there was no significant difference for tea 
consumption (Table 2). A slightly higher but statistically significant proportion of controls 
reported drinking green tea (7% of cases and 9% of controls). Most people in both groups 
were or had been smokers, but the proportion was significantly higher in controls (83%) than 
cases (72%). Regular cannabis use was about three times more common among the controls 
(27%) than cases (9%) (Table 2) but the proportion decreased with age (in both cases and 
controls) and the case-control difference was non-significant in patients aged over 60 years 
(Figure 1(a)). 
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Mean BMI was higher among the cases than the controls (Table 2). Because this difference 
might be secondary to the disease, e.g. through fluid retention in the cases or through 
inadequate diet in the controls, we also compared patients’ pre-morbid BMI. This was 
estimated from participants’ reports on their weight at age 40 (for those over 40) or else at 
age 20, with the intention of avoiding effects of the disease on BMI. Again, there was a 
highly significant difference with the cases having a higher mean for this measure of obesity. 
A larger proportion of cases, 262 out of 1280, but only 48 out of 734 controls were reported 
to be diabetic (Odds Ratio 3.68, 95% CI 2.66 to 5.08) (Table 2). Information about whether 
reported diabetes was Type 1 or Type 2 was not available. As expected, the prevalence of 
diabetes increased with age (Figure 1(b)), and diabetes was significantly associated with 
cirrhosis risk only in patients aged over 40 years. 
We also tested whether the differences between cases and controls showed variation between 
countries, with results shown in Supplementary Table 4. 
When all the risk factors were tested together, using multiple logistic regression to identify 
independent effects on risk of alcohol-related cirrhosis (Table 3), the most significant effects 
were from cannabis use (protective), coffee and possibly tea consumption (each decreasing 
risk to a similar extent). Diabetes and pre-morbid BMI, but not current BMI, were associated 
with increased risk. 
GenomALC participants – family history 
Among those whose fathers had a reported alcohol problem, 21.5% of cases versus 9.4% of 
controls reported that their fathers died of liver disease (OR 2.64, 95% CI 1.68 to 4.14). 
Among those whose mothers had a reported alcohol problem, 17.9% of cases versus 12.5% 
of controls reported that their mothers died of liver disease (OR 1.53, 95% CI 0.79 to 2.97).  
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We also tested for differential effects by sex of the participants, analysing effects on sons and 
daughters (male and female patients) separately (Figure 2). Risk of cirrhosis was significantly 
increased in both male and female patients if the Father was reported as excessive alcohol 
user and to have died from liver disease. There were trends towards increased risk in both 
sexes if the Mother was affected, but these did not reach statistical significance. Combining 
data from all four groups gave an odds ratio of 2.25 (95% CI 1.55 – 3.26).  
UK Biobank – case-control comparisons 
Means and distributions of alcohol-related characteristics for cases and controls from UK 
Biobank are shown in Supplementary Table 3. Ages were similar, but reported alcohol intake 
differed substantially, largely because of the minimum current drinking level required for 
controls but not cases, but perhaps also from reduction or cessation of alcohol intake by cases 
with poor health. 
There were significant differences (Table 4) between cases and controls for prevalence of 
diabetes, obesity, coffee consumption, and smoking but not for cannabis use. Beverage 
preferences also differed significantly, with controls taking a higher proportion of their 
alcohol as wine (32%, against 26% for cases) and cases taking a higher proportion as spirits 
(15%, against 8% for controls). 
To test all potential risk factors simultaneously and attempt to identify independent effects, 
multivariate logistic regression was performed with results shown in Table 5. Cannabis use 
was excluded from the multivariate analyses because it was only available for a subset of the 
UK Biobank participants and its inclusion in an analysis involving listwise deletion greatly 
reduced the available numbers. Coffee and tea consumption, measures of obesity and 
prevalence of diabetes were independently significant. When both BMI and WHR were 
included, their effects were in opposite directions, with higher WHR associated with higher 
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risk and higher BMI with lower risk. In this analysis, the proportion of alcohol taken as sprits 
was independently significant but the proportion as wine was not. 
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DISCUSSION 
We have a number of important findings about factors associated with alcohol-related 
cirrhosis in high-risk drinkers. The novelty of the study lies in the fact that we used high-risk 
drinkers as controls, and well-defined selection of cases and controls allowed evaluation of 
the factors specifically altering risk for alcohol-related cirrhosis. Importantly, validation in an 
independent cohort enhances confidence in our results. Unlike previous studies that reported 
association with individual risk factors for alcohol-related cirrhosis, our study has 
simultaneously evaluated multiple potential aspects of risk in well characterised large cohorts 
of high-risk drinkers. 
Alcohol use 
Aspects of alcohol use, other than quantity, differed significantly between cases and controls 
and may affect risk of developing cirrhosis. In the GenomALC data, a higher proportion of 
total alcohol intake as wine was observed in the control group. When considered in the 
logistic regression model, a higher proportion of alcohol as wine was significantly associated 
with lower risk of cirrhosis but drinking with or between meals had no significant effect. The 
differential effect of wine, compared to other alcoholic beverages, is consistent with results of 
several previous studies (30-32) but we cannot distinguish between direct effects from some 
components of wine and confounding by other characteristics of drinkers who prefer wine. 
Nor can we be sure that we are seeing a protective effect of wine rather than a harmful effect 
associated with a preference for other beverages, because the UK Biobank data suggest that a 
higher proportion of alcohol taken as spirits is associated with higher risk of cirrhosis. It 
would be inappropriate, and potentially harmful, to infer that wine consumption is beneficial. 
Tea and coffee 
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We found replicated evidence for a protective effect of coffee consumption. In the 
GenomALC case-control comparison (Table 2) controls were more likely to have been a 
coffee drinker during the period of excessive drinking and to have drunk more coffee per day. 
In the UK Biobank data the number of cups of coffee per day was higher among the controls 
than cases (Table 4). These results are consistent with the reported protective effects of coffee 
on liver disease (14, 33), on liver function test abnormality (14, 34, 35), and (at least in 
moderate amounts) on overall mortality (36). This is the first study to demonstrate an 
independent association of coffee in subjects with well-characterised alcohol use and 
cirrhosis directly assessed for this analysis. However, there is still uncertainty about which 
components of coffee confer protection and whether it is protective after liver damage is 
already present.  
The GenomALC case-control comparison showed marginally significant protective effects of 
tea consumption when both tea and coffee were included in the multivariate analysis (Table 
3). At least among the cases, tea and coffee tended to be alternative beverages; tea drinkers 
were less likely to drink coffee and vice versa.  There were not many users of green tea 
(<10%) in our cohort, and there was only marginally significant protective effect (Table 2). In 
similar UK Biobank comparisons, coffee and tea were each significantly associated with 
lower risk and had comparable effect sizes (Table 5).  
Other substance use 
Smoking was more common among controls than cases in the GenomALC participants 
(Table 2), and the UK Biobank data confirmed this (Table 4) with current smoking being 
more frequent and never smoking being less frequent in the controls. One interpretation could 
be that smoking is protective against cirrhosis, but this is contrary to its effects on most 
diseases and cannot be accepted without other evidence. It is possible that cases had more 
contact with the healthcare system than controls and had received more intensive and 
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effective counselling about the risks of smoking, but this would not have affected the 
proportions who had never smoked. Even if smoking were protective against cirrhosis, its 
adverse impact on cardiovascular and respiratory diseases and cancers would outweigh any 
benefits. 
There has been uncertainty about whether cannabis use is protective or harmful. However, a 
recent study of over 300,000 people with a past or current history of abusive alcohol use 
showed that cannabis use was associated with lower ORs for all stages of alcohol-related 
liver disease (19). Our GenomALC data showing cannabis use was more common among the 
controls confirms this (Table 2). In addition, multivariate regression in the GenomALC 
cohort corroborated the association of cannabis as an independent protective factor for 
cirrhosis (37-39). Nevertheless many of the controls were recruited from addiction clinics and 
may have had other substance use disorders (including for cannabis) that could confound 
these results. In the UK Biobank, cannabis use had no significant effect but the proportion of 
participants with information on cannabis use was small. We observed that among 
GenomALC participants, younger patients were more likely to have used cannabis (Figure 
1(a)) but the ORs associated with reported cannabis use were consistent across age groups. 
There is independent evidence for a biological link between liver damage and cannabinoids 
and/or cannabinoid receptors (37-39), and for the therapeutic potential of several components 
of the cannabinoid system against liver cirrhosis (40).  
Obesity, diabetes and metabolic risk 
Our expectation, based on previous reports, was that obesity would be a risk factor for 
cirrhosis. This was confirmed in the GenomALC case-control comparison (Table 2), and 
when the effects of obesity and diabetes were considered together (Table 3) both were 
independently significant. Distinction between type 1 and type 2 diabetes was not specifically 
recorded in our data, but over 90% would be expected to be type 2 given the age range of our 
Page 20 of 38 
 
study participants (41). Results in the UK Biobank were similar (Tables 4, 5) but waist/hip 
ratio showed a stronger association than BMI. Prevalence of diabetes increased with age, as 
expected (Figure 1(b)), and high-risk drinkers who have diabetes in middle age are 
particularly likely to progress to cirrhosis. The association between obesity and/or diabetes 
and risk of cirrhosis, including alcohol-related cirrhosis, has been described in community 
based cohort studies (42-44) and may reflect a similarity with non-alcoholic liver disease, 
which is related to metabolic syndrome and dysregulation of carbohydrate and lipid 
metabolism. 
Family History 
Our data show that risk of alcohol-related liver disease is transmitted in families, as we 
previously reported for a subset of our patients (24). Familial/genetic risk is well-established 
for excessive alcohol intake or alcohol dependence (21), but not for the medical 
complications of alcohol use such as cirrhosis. The transmission from fathers to offspring was 
statistically significant, with a trend for similar risk transmission from mothers (Figure 2). 
This apparent difference in risk transmission from fathers and from mothers is likely due to 
chance, to lower incidence of cirrhosis in mothers (i.e. insufficient power) and/or recall bias 
by the study participants. Transmission of risk from parents to offspring is likely to be 
genetic, given the discovery in recent years of loci associated with alcohol-related cirrhosis 
(25, 26, 45). If differential transmission of risk from fathers and mothers is a real 
phenomenon, it may be mediated through genetic/epigenetic imprinting or other mechanisms 
of selective transmission from father versus mother; multigenerational epigenetic adaptation 
to hepatic wound healing response has been elucidated in animal models (46). Confirming or 
refuting such differential transmission will require replication in other studies with family 
data, or molecular studies on epigenetic changes in candidate genes (47). 
Strengths and limitations 
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Our study design has both strengths and weaknesses. One of the issues to be addressed in 
planning a case-control study is the choice of appropriate criteria for the two groups. For the 
GenomALC cases, we restricted our recruitment to patients with alcohol-related cirrhosis and 
definition of criteria for this did not present any significant difficulty. The choice of controls 
was more complex; it is necessary to have a control group with alcohol intake which puts 
them at risk of cirrhosis and with similar lifetime alcohol exposure to the cases. In practice 
we recruited controls from clinics for treatment of substance use disorders and from 
detoxification facilities, accepting the risk that these controls might have different pattern of 
psychiatric comorbidities from the cases. In the data analysis, we sought to overcome the 
problem of non-causative differences between the GenomALC cases and controls by 
checking for consistency with results from a population-based second source of data, the UK 
Biobank. 
The recruitment of GenomALC participants in six countries is a source of strength in that it 
provides diversity and allows comparison of results (see Supplementary Table 4). In general 
the results do not differ significantly across countries, except for cannabis use and possibly 
smoking status where heterogeneity is driven by stronger effects in France. The GenomALC 
participants were mostly of European descent and the extent to which our results can be 
generalised to other populations remains to be determined. 
From the UK Biobank data, diagnoses of alcohol-related cirrhosis or alcohol-related liver 
disease were based on hospital discharge diagnoses or death certification. For the control 
group from UK Biobank, we cannot exclude liver disease and if it was present in a substantial 
proportion of these controls then power to detect effects on risk would be reduced. However, 
any such reduction in power may be mitigated by the much larger number of controls in the 
UK Biobank dataset. Reduction in power would lead to a failure to find a true difference 
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between cases and controls (false negative result) rather than producing a significant but false 
difference (false positive). 
The GenomALC study was not prospective as patients were assessed after diagnosis, 
however the research questions were planned and the data collected were for the purposes of 
these analyses. The lack of prospective design is not a problem for assessment of genetic risk 
for which these patients were primarily recruited, but recall may be biased by patients’ 
knowledge of their diagnosis, and some of the postulated risk factors such as BMI may 
change as a consequence of disease. Case-control differences may be causative but could also 
be due to modes of recruitment (particularly for other drug use, including smoking). Methods 
using instrumental variables such as Mendelian Randomisation can address causation, but 
they depend on genetic association results being available for the postulated causative factors. 
Study design included definition of data and samples to be collected, but it is inevitable that 
questions will arise, often due to other research published during the course of a study, that 
were not envisaged at the outset. Although we have identified multiple risk factors for 
development of cirrhosis among high-risk drinkers, there are other factors such as variation in 
the microbiome (48), perhaps in turn associated with obesity, or infection with hepatotropic 
viruses other than B or C (49), about which we have no data.  
A further limitation, which applies to many epidemiological studies, is that associations with 
risk may not reflect cause-and-effect relationships. For all risk factors, but particularly for the 
apparent effects of smoking, cannabis use and beverage preference (wine versus spirits) 
unmeasured confounders could produce the observed associations and we caution against 
changes in these areas without further evidence. 
Conclusions 
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We identified significant associations between family history of liver disease; diabetes and 
obesity; tea, coffee, wine and cannabis consumption, and risk of cirrhosis. Our findings may 
have public health consequences if the causal relationships can be confirmed; measures such 
as weight loss, intensive treatment of diabetes or pre-diabetic states, and encouragement of 
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Table 1. Comparison of alcohol consumption in cases and controls from the GenomALC study. Results are 
shown as means ± SEM. For the log-transformed alcohol measures, grams of alcohol per day and lifetime 
alcohol consumption, the means converted back to grams or kilograms (geometric means) are shown in 
italics. 








 Male (978 cases, 555 controls) 
Controls 49.8 ± 0.41 2.333 ± 0.0010 
215 grams 
21.9 ± 0.40 3.192 ± 0.013 
1556 kg 
Cases 52.4 ± 0.28 2.282 ± 0.0095 
191 grams 
25.1 ± 0.36 3.195 ± 0.011 
1566 kg 
p-values 5.06 x 10-8 5.26 x 10-4 1.06 x 10-8 0.882 
 Female (315 cases, 199 controls) 
Controls 50.7 ± 0.72 2.239 ± 0.0167 
173 grams 
18.57 ± 0.53 3.034 ± 0.020 
1082 kg 
Cases 50.3 ± 0.52 2.160 ± 0.0016 
144 grams 
19.4 ± 0.53 2.960 ± 0.020 
912 kg 
p-values 0.603 0.0013 0.288 0.013 
 All (1293 Cases, 754 Controls) 
Controls 50.0 ± 0.36 2.308 ± 0.0085 
203 grams 
21.0 ± 0.33 3.150 ± 0.011 
1412 kg 
Cases 51.9 ± 0.25 2.252 ± 0.0084 
179 grams 
23.7 ± 0.31 3.138 ± 0.010 
1374 kg 
p-values 1.10 x 10-5 1.30 x 10-5 1.23 x 10-8 0.426 
  
Page 29 of 38 
 
Table 2. Putative risk factors compared (one at a time) in the GenomALC  cases and controls. N for the 
tested risk factors varied from 1070 to 1293 for cases and from 609 to 754 for controls. Means ± SE, or 
proportions. 
 Controls Cases p-value 
Beer, percent of total alcohol* 44.7 ± 1.58  41.7 ± 1.22  0.130 
Wine, percent of total alcohol* 37.7 ± 1.66  30.1 ± 1.18  1.76 x 10-4 
Spirits, percent of total alcohol* 35.1 ± 1.53  38.2 ± 1.22  0.124 
Other, percent of total alcohol* 5.5 ± 0.93 7.6 ± 0.78 0.101 
Usually drink with meals /  






BMI, kg/m2 25.51 ± 0.19 27.47 ± 0.16 3.55 x 10-14 
Premorbid BMI, kg/m2 24.44 ± 0.18 26.37 ± 0.15 5.77 x 10-15 
Diabetes present 48 out of 734 (6.5%) 262 out of 1280 (20.5%) 2.27 x 10-18 
Tea drinker 185 out of 751 (24.6%) 273 out of 1288 (21.2%) 0.078 
Tea, cups per day† 3.10 ± 0.23 3.07 ± 0.19 0.933 
Green Tea drinker 70 out of 749 (9.3%) 85 out of 1283 (6.6%) 0.030 
Green Tea, cups per day† 2.41 ± 0.22 2.29 ± 0.19 0.664 
Coffee drinker 502 out of 753 (66.7%) 685 out of 1290 (53.1%) 1.91 x 10-9 
Coffee, cups per day† 4.06 ± 0.19 3.46 ± 0.12 0.0053 
Smoking, Ever 624 out of 754 (82.8%) 929 out of 1293 (71.8%) 1.72 x 10-8 
Cannabis user > 5 years 200 out of 747 (26.8%) 121 out of 1287 (9.4%) 4.22 x 10-24 
* Note that although the percentages of alcohol as beer, wines, spirits or other for each person sum to 
100%, the mean percentages for cases or controls do not. When the comparison was repeated using 
the non-parametric Mann-Whitney U-test the results were similar; percentage of alcohol as wine 
differed significantly (p < 0.001) between cases and controls but percentages as beer, spirits or other 
alcoholic beverages did not (p > 0.05). 
† In participants who reported drinking tea/green tea/coffee, as appropriate.  
Page 30 of 38 
 
Table 3. Putative risk factors compared in the GenomALC cases and controls, using multivariate logistic 
regression to identify independent effects. Sex, age, daily alcohol intake and duration of excessive drinking 
are included to adjust for any deviation from case-control matching. N = 1362 with data on all of he listed 
predictors. OR, odds ratio per unit change in predictor variable; 95% CI, 95% confidence intervals. 
 
 OR 95% CI p-value 
Variables in the equation:    
Cannabis user (0=No, 1=Yes) 0.331 0.237 – 0.464 1.18 x 10-10 
Diabetic (0=No, 1=Yes) 3.086 2.020 – 4.715 1.85 x 10-7 
Premorbid BMI, kg/m2 1.057 1.031– 1.0884 1.12 x 10-5 
Coffee drinker (0=No, 1=Yes) 0.643 0.498 – 0.830 6.87 x 10-4 
Ever smoker (0=No, 1=Yes) 0.619 0.450 – 0.853 0.0033 
Tea drinker (0=No, 1=Yes) 0.701 0.517 – 0.952 0.023 
Spirits, percent of total 1.004 1.001 – 1.007 0.019 
Duration of excessive drinking, years 1.024 1.012 – 1.036 1.39 x 10-4 
Variables not in the equation:    
Sex   0.438 
Age, years   0.944 
Alcohol intake, grams/day   0.223 
BMI, kg/m2   0.122 
Wine, percent of total   0.549 
Drink with meals?   0.413 
Green tea drinker (0=No, 1=Yes)   0.897 
Beer, percent of total   0.447 
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Table 4. Putative risk factors compared (one at a time) in the UK Biobank participants. 
Means ± SE and N, or proportions. 
 
 Controls Cases p-value 
BMI, kg/m2 28.05 ± 0.06 (6534) 28.87 ± 0.27 (401) 6.51 x 10-4 
Waist/Hip Ratio 0.931 ± 0.001 (6550) 0.969 ± 0.004 (403) 7.67 x 10-20 
Diabetes present 353 out of 6573 (5.4%) 122 out of 407 (30.0%) 4.05 x 10-50 
Red or white wine, percent of total 
alcohol 
32.3 ± 0.44% (6515) 25.9 ± 2.12% (251) 0.0049 
Beer or cider, percent of total alcohol 58.4 ± 0.47% (6525) 57.4 ± 2.53% (253) 0.679 
Spirits, percent of total alcohol 8.4 ± 0.23% (6526) 15.4 ± 1.72% (254) 9.65 x 10-9 
Tea, cups per day 3.24 ± 0.04 (6298) 3.13 ± 0.18 (382) 0.512 
Coffee, cups per day 2.18 ± 0.03 (6064) 1.91 ± 0.12 (366) 0.026 
Smoking, Ever 4895 out of 6557 (74.7%) 283 out of 404 (70.0%) 0.046 
Cannabis (ordinal measure of number 
of occasions) 
0.930 ± 0.034 (1518) 0.871 ± 0.211 (31) 0.805 
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Table 5. Putative risk factors compared in the UK Biobank cases and controls. Multivariate logistic 
regression with stepwise inclusion of potential predictors of case-control status, to identify independent and 
significant effects. Sex and age are included to adjust for any deviation from case-control matching. OR, 
odds ratio per unit change in predictor variable; 95% CI, 95% confidence intervals. Note that cannabis 
information is not included as a potential predictor because it would reduce the available numbers too 
greatly. 
 
 OR 95% CI p-value 
Variables in the equation:    
Diabetic (0=No, 1=Yes) 6.25 4.41 – 8.86 6.21 x 10-25 
Waist/Hip Ratio (WHR x 100) 1.062 1.040 – 1.084 2.28 x 10-8 
Spirits, percent of total alcohol 1.011 1.006 - 1.017 8.51 x 10-5 
Body mass index, kg/m2 0.940 0.908 – 0.974 5.90 x 10-4 
Tea (cups per day) 0.928 0.877 - 0.981 0.0088 
Coffee (cups per day) 0.915 0.851 - 0.984 0.017 
Variables not in the equation:    
Sex   0.088 
Smoking (Ever)   0.156 
Age, years   0.589 
Red or white wine, percent of total alcohol   0.681 
Beer or cider, percent of total alcohol   0.834 
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LEGENDS TO FIGURES 
 
Figure 1. Prevalence and Odds Ratios (ORs) by age group for (a) reported cannabis use, (b) 
diabetes, in GenomALC cases and controls. For cannabis use, Odds Ratios did not show 
significant heterogeneity between age groups (p = 0.200) but for diabetes Odds Ratios 
showed significant heterogeneity between age groups (p = 0.0044). 
 
Figure 2. Odds ratios for alcoholic cirrhosis in male and female GenomALC participants, by 
reported parental death from liver disease (if the parent was reported to have had alcohol 
problems). 
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of recruitment, Supp 
Table 4 and Supp Fig 1 
Discussion  
Key results 18 Summarise key results with reference to study 
objectives 
Pg 17-20 
Limitations 19 Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
Pg 21 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
Pg 22 
Generalisability 21 Discuss the generalisability (external validity) of the 
study results 
p. 21, (consistency 
between two sources of 
data (GenomALC, UK 
Biobank). 
Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 




*Give information separately for cases and controls. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of 
Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at http://www.strobe-statement.org. 
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Study Highlights 
What is known: 
 Lifetime alcohol exposure reported by patients with alcohol-related cirrhosis varies 
widely, and only some high-risk drinkers develop cirrhosis 
What is new here:  
 Susceptibility to cirrhosis among high-risk drinkers is affected by family history of 
alcohol-related liver disease 
 Effects of obesity, diabetes, coffee consumption and beverage preference have been 
confirmed in data from two independent studies and this information should help in 
preventing or delaying cirrhosis in patients whose drinking places them at risk. 
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ABSTRACT 
Background: Sustained high alcohol intake is necessary but not sufficient to produce 
alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, 
would assist in discovery of mechanisms and prediction of risk.  
Methods: We conducted a multi-centre case-control study (GenomALC) comparing 1293 
cases (with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol 
exposure but no evidence of liver disease, 73.6% male). Information confirming or excluding 
cirrhosis, and on alcohol intake and other potential risk factors, was obtained from clinical 
records and by interview. Case-control differences in risk factors discovered in the 
GenomALC participants were validated using similar data from 407 cases and 6573 controls 
from UK Biobank. 
Results: The GenomALC case and control groups reported similar lifetime alcohol intake 
(1374 versus 1412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1288) versus 
6.5% (48/734), p = 2.27 x 10-18) and higher pre-morbid BMI (26.37 ± 0.16 kg/m2) than 
controls (24.44 ± 0.18 kg/m2, p = 5.77 x 10-15). Controls were significantly more likely to 
have been wine drinkers, coffee drinkers, smokers and cannabis users than cases. Cases 
reported a higher proportion of parents who died from liver disease than controls (OR 2.25 
95% CI 1.55 to 3.26). Data from UK Biobank confirmed these findings for diabetes, BMI, 
proportion of alcohol as wine and coffee consumption.  
Conclusions: If these relationships are causal, measures such as weight loss, intensive 
treatment of diabetes or pre-diabetic states, and coffee consumption should reduce risk of 
alcohol-related cirrhosis.  
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Sustained high alcohol intake, often associated with alcohol dependence, can lead to alcohol-
related liver diseases including cirrhosis. The usual progression is through fatty liver, 
frequent in high-risk drinkers but reversible with abstinence, to fibrosis and cirrhosis. Some 
patients will develop alcoholic hepatitis, and some will develop hepatocellular carcinoma 
(HCC), generally with cirrhosis as a precursor. Therefore, cirrhosis is not only the end-stage 
of liver damage, but also increases risk for other life-threatening conditions. Apart from 
abstinence from alcohol, supportive measures, and liver transplantation in selected abstinent 
patients, current treatment options for alcohol-related cirrhosis are limited. 
The relationship between alcohol intake and cirrhosis has been recognised since the late 
eighteenth century (1), with subsequent efforts to quantify this association made by 
Pequignot (2) who noted an increased risk of cirrhosis in people drinking more than 40 grams 
of alcohol per day. It is known that women are more susceptible to liver damage from alcohol 
than men (3), and larger studies and meta-analyses (4) have refined the threshold for 
detectable risk from alcohol intake.  
It is notable that only a minority of high-risk drinkers develop cirrhosis. It is difficult to find 
reliable estimates, but in Denmark 7.7% of patients diagnosed with harmful alcohol use and 
8.8% of those diagnosed with alcohol dependence developed cirrhosis over the subsequent 15 
years (5). Meta-analysis (6) showed that 7-16% of people in alcohol problem cohorts had 
cirrhosis after 8-12 years. Variation in susceptibility may be due to genetic variation, and/or 
presence of other environmental and lifestyle risk factors which increase the probability of 
liver damage. Apart from alcohol intake and gender, obesity (also associated with non-
alcoholic liver disease) has the strongest evidence for increasing risk of alcohol-related 
cirrhosis. For instance, liver biopsy histology showed more severe abnormalities in patients 
with alcohol use disorders with greater body weight (7); this was confirmed in a subsequent 
study (8) which showed that being overweight was a risk factor for steatosis, hepatitis and 
Page 8 of 38 
 
cirrhosis in addition to the effects of age, gender and duration of alcohol abuse. Other studies 
have also found an association between obesity or body mass index (BMI) and liver disease 
(9, 10), fibrosis (11), alcoholic hepatitis (12) or HCC (13). There is evidence that coffee or 
tea consumption can reduce risk of liver disease or favourably affect biomarkers associated 
with liver disease (14-17). Smoking has been associated with increased risk of alcohol-related 
cirrhosis and of cirrhosis in general, particularly among women (18). A recent report showed 
that cannabis use protected against liver disease in patients with alcohol use disorders (19), 
possibly through effects on inflammation mediated by cannabinoid receptors (20).  
There is a lack of hard data from twin or family studies on genetic risk for alcohol-related 
cirrhosis. Alcohol dependence is partially heritable (21) but twin studies on its consequences 
such as alcohol-related liver disease (22) have been limited by small numbers and lack of 
adjustment for heritable effects on alcohol exposure (23). Our earlier report (24) suggested 
that a history of liver disease in a parent with alcohol problems was associated with increased 
risk of alcohol-related cirrhosis. The known genetic risk loci for cirrhosis in PNPLA3 and 
HSD17B13 (25, 26) are associated with lipid metabolism and potentially with metabolic 
changes which accompany obesity. 
The GenomALC Consortium (24) was initiated to gather data and samples for identification 
of risk factors for alcohol-related cirrhosis, including a case-control genetic association study. 
In this paper we focus on comparison of case and control groups for potential clinical and 
phenotype factors that alter disease risk including beverage preference, other substance use, 
family history, obesity and diabetes. Where we have identified potential risk-altering factors 
from our data, we have attempted validation using comparable data from the UK Biobank. 
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SUBJECTS AND METHODS 
GenomALC Study 
Recruitment and data collection were based on our published GenomALC protocol (24). Two 
groups of patients were recruited between 2012 and 2017 in six countries (Australia, France, 
Germany, Switzerland, UK and USA).. Cases were recruited through hepatology clinics and 
controls were recruited from psychiatric clinics or detoxification facilities. All participants 
gave written informed consent. The study was approved by appropriate Ethics Committees or 
Institutional Review Board at each site and conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. Data and samples were identified by a study-specific code with no 
personal information. 
To be confident that participants either had or were at substantial risk of alcohol-related 
cirrhosis and to minimise the chance that cirrhosis was caused by factors other than alcohol, 
we recruited patients with alcohol intake of at least 80 grams per day for men and 50 grams 
per day for women for 10 years or more. Both cases and controls were required to have 
negative test results (antibody/antigen/viral load) for hepatitis B and C, and no clinical or 
serological evidence of human immunodeficiency virus (HIV). Unequivocal evidence of 
cirrhosis in cases was defined as imaging results (sonography, computed tomography, 
magnetic resonance imaging) compatible with cirrhosis; together with detectable ascites by 
imaging or paracentesis, and/or grade 2 or higher spontaneous hepatic encephalopathy, and/or 
moderate or large oesophageal varices on upper gastrointestinal endoscopy. Histological 
cirrhosis on biopsy was defined as Metavir fibrosis stage F4 or Ishak fibrosis stage 5 or 6. 
Liver stiffness (Fibroscan®) was accepted as diagnostic for cirrhosis if greater than 22 kPa in 
the presence of aspartate aminotransferase (AST) less than 100 u/l or ≥30 kPa if AST 
between 100-200 IU/L (27, 28) . Other causes of liver disease, including haemochromatosis, 
Wilson’s Disease, and autoimmune liver disease were excluded by laboratory tests or clinical 
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criteria, and any patient who had received a liver transplant for a condition other than 
alcohol-related cirrhosis was also excluded. Controls met the alcohol intake criteria but with 
no evidence or history of liver disease, had normal results for liver function tests (AST, 
alanine aminotransferase (ALT), bilirubin, albumin, but not necessarily for gammaglutamyl 
transferase (GGT)), platelet count and International Normalised Ratio (INR), and/or had less 
than 6 kPa liver stiffness (Fibroscan®), while drinking or within seven days of abstinence. 
Information was collected on demographics, self-reported ancestry, history of alcohol, 
tobacco and cannabis use, tea and coffee consumption, clinical symptoms, biopsy results if 
available, and biochemical and haematological test results. The data collection form (24) is 
available from the corresponding authors. Data were transferred to a central site, checked for 
anomalies and if necessary corrected after clarification, and stored in a secure password-
protected system.  
Analysis of familial transmission of risk for alcohol-related cirrhosis was based on 
participants’ responses to questions about their parents: 
a. Did your father have problems with alcohol?           
b. If YES, did he die of liver disease?       
c. Did your mother have problems with alcohol?        
d. If YES, did she die of liver disease? 
This analysis was restricted to patients whose fathers or mothers were reported to have had 
‘problems with alcohol’, and assumes that death from liver disease in a parent with alcohol 
problems is due to alcohol-related liver disease (potentially alcoholic hepatitis or HCC, as 
well as alcohol-related cirrhosis). 
UK Biobank 
Data from the UK Biobank (https://www.ukbiobank.ac.uk/, accessed 2018-11-07) on a 
population cohort of 502,616 participants from the UK were made available under approval 
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number 18870. Baseline assessment included a demographic, lifestyle and health 
questionnaire and participants agreed to have their health records accessed for baseline and 
follow-up outcomes (29). Participants had given informed consent as described at 
http://www.ukbiobank.ac.uk/wp-content/uploads/2011/06/Consent_form.pdf and ethical 
approval was given under the UK Biobank Ethics and Governance framework 
(https://egcukbiobank.org.uk/). 
For this analysis we extracted information on people who  
(1) reported alcohol intake of ≥80 grams/day for men or ≥50 grams/day for women at the 
time of assessment, with self-reported similar or greater alcohol intake ten years 
previously, and no reported alcohol-related cirrhosis or other alcohol-related liver 
disease (controls, N = 6573); or  
(2) had a diagnosis of alcohol-related cirrhosis (ICD10 code K70.3) (cases, N = 407).  
Relevant information on these UK Biobank participants included age, sex, calculated BMI, 
waist/hip ratio (WHR), self-reported current alcohol intake, daily tea and coffee consumption, 
smoking status (never, former or current smoker), cannabis use (ever), and diabetes status 
(self-reported in response to the touchscreen question ‘Has a doctor ever told you that you 
have diabetes?’ and if Yes, confirmed by interview).  
Data analysis 
Data analyses used SPSS Version 22 (IBM Corp., 590 Madison Avenue New York, NY 
10022). Alpha (p-value) <0.05 and Odds Ratio (OR) when 95% Confidence Interval (CI) 
excluded 1.00 were considered significant. Statistical tests for differences between case and 
control groups were based on contingency tests for categorical variables, and ANOVA for 
quantitative variables. Logistic regression analysis to evaluate independent predictors was 
based on stepwise entry until all significant (p < 0.05) variables had been entered. For 
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evaluation of the effects of family history, the possibility of differential transmission of 
effects to male and female patients was taken into account using patient sex for stratification, 
testing for heterogeneity of OR across strata with the Breslow-Day test and, if no 
heterogeneity was found, estimating the common OR. Similarly, for testing whether case-
control differences were consistent across country of recruitment, countries were treated as 
the strata and heterogeneity and common odds ratios were evaluated. 
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RESULTS 
GenomALC participants – case-control comparisons 
1293 cases and 754 controls were recruited between 2012 and 2017. There were 978 male 
and 315 female cases, and 555 male and 199 female controls. Clinical features of the cases 
are summarised in Supplementary Table 1. Most participants reported only ‘European’ 
ancestry, with the highest proportion in Germany (99%) and lowest in the US (88%).  
Cases drank significantly less alcohol per day than controls, but had been drinking for 
significantly longer. Total lifetime alcohol intake did not differ significantly between male 
cases and controls, and in female cases was slightly lower than for controls (Table 1). A 
breakdown by country of recruitment is given in Supplementary Table 2, with comparisons of 
lifetime alcohol intake in cases and controls by country in Supplementary Figure 1. Controls 
reported taking a significantly higher proportion of their total alcohol in the form of wine 
(Table 2), but were less likely to report usually drinking with (rather than between) meals.  
Forty eight percent of cases but only 28% of controls were currently living with a spouse or 
partner. There was no significant difference in years of education. Controls were more likely 
than cases to have been coffee drinkers during the time they were drinking alcohol heavily, 
and to have drunk more coffee per day, but there was no significant difference for tea 
consumption (Table 2). A slightly higher but statistically significant proportion of controls 
reported drinking green tea (7% of cases and 9% of controls). Most people in both groups 
were or had been smokers, but the proportion was significantly higher in controls (83%) than 
cases (72%). Regular cannabis use was about three times more common among the controls 
(27%) than cases (9%) (Table 2) but the proportion decreased with age (in both cases and 
controls) and the case-control difference was non-significant in patients aged over 60 years 
(Figure 1(a)). 
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Mean BMI was higher among the cases than the controls (Table 2). Because this difference 
might be secondary to the disease, e.g. through fluid retention in the cases or through 
inadequate diet in the controls, we also compared patients’ pre-morbid BMI. This was 
estimated from participants’ reports on their weight at age 40 (for those over 40) or else at 
age 20, with the intention of avoiding effects of the disease on BMI. Again, there was a 
highly significant difference with the cases having a higher mean for this measure of obesity. 
A larger proportion of cases, 262 out of 1280, but only 48 out of 734 controls were reported 
to be diabetic (Odds Ratio 3.68, 95% CI 2.66 to 5.08) (Table 2). Information about whether 
reported diabetes was Type 1 or Type 2 was not available. As expected, the prevalence of 
diabetes increased with age (Figure 1(b)), and diabetes was significantly associated with 
cirrhosis risk only in patients aged over 40 years. 
We also tested whether the differences between cases and controls showed variation between 
countries, with results shown in Supplementary Table 4. 
When all the risk factors were tested together, using multiple logistic regression to identify 
independent effects on risk of alcohol-related cirrhosis (Table 3), the most significant effects 
were from cannabis use (protective), coffee and possibly tea consumption (each decreasing 
risk to a similar extent). Diabetes and pre-morbid BMI, but not current BMI, were associated 
with increased risk. 
GenomALC participants – family history 
Among those whose fathers had a reported alcohol problem, 21.5% of cases versus 9.4% of 
controls reported that their fathers died of liver disease (OR 2.64, 95% CI 1.68 to 4.14). 
Among those whose mothers had a reported alcohol problem, 17.9% of cases versus 12.5% 
of controls reported that their mothers died of liver disease (OR 1.53, 95% CI 0.79 to 2.97).  
 
Page 15 of 38 
 
We also tested for differential effects by sex of the participants, analysing effects on sons and 
daughters (male and female patients) separately (Figure 2). Risk of cirrhosis was significantly 
increased in both male and female patients if the Father was reported as excessive alcohol 
user and to have died from liver disease. There were trends towards increased risk in both 
sexes if the Mother was affected, but these did not reach statistical significance. Combining 
data from all four groups gave an odds ratio of 2.25 (95% CI 1.55 – 3.26).  
UK Biobank – case-control comparisons 
Means and distributions of alcohol-related characteristics for cases and controls from UK 
Biobank are shown in Supplementary Table 3. Ages were similar, but reported alcohol intake 
differed substantially, largely because of the minimum current drinking level required for 
controls but not cases, but perhaps also from reduction or cessation of alcohol intake by cases 
with poor health. 
There were significant differences (Table 4) between cases and controls for prevalence of 
diabetes, obesity, coffee consumption, and smoking but not for cannabis use. Beverage 
preferences also differed significantly, with controls taking a higher proportion of their 
alcohol as wine (32%, against 26% for cases) and cases taking a higher proportion as spirits 
(15%, against 8% for controls). 
To test all potential risk factors simultaneously and attempt to identify independent effects, 
multivariate logistic regression was performed with results shown in Table 5. Cannabis use 
was excluded from the multivariate analyses because it was only available for a subset of the 
UK Biobank participants and its inclusion in an analysis involving listwise deletion greatly 
reduced the available numbers. Coffee and tea consumption, measures of obesity and 
prevalence of diabetes were independently significant. When both BMI and WHR were 
included, their effects were in opposite directions, with higher WHR associated with higher 
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risk and higher BMI with lower risk. In this analysis, the proportion of alcohol taken as sprits 
was independently significant but the proportion as wine was not. 
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DISCUSSION 
We have a number of important findings about factors associated with alcohol-related 
cirrhosis in high-risk drinkers. The novelty of the study lies in the fact that we used high-risk 
drinkers as controls, and well-defined selection of cases and controls allowed evaluation of 
the factors specifically altering risk for alcohol-related cirrhosis. Importantly, validation in an 
independent cohort enhances confidence in our results. Unlike previous studies that reported 
association with individual risk factors for alcohol-related cirrhosis, our study has 
simultaneously evaluated multiple potential aspects of risk in well characterised large cohorts 
of high-risk drinkers. 
Alcohol use 
Aspects of alcohol use, other than quantity, differed significantly between cases and controls 
and may affect risk of developing cirrhosis. In the GenomALC data, a higher proportion of 
total alcohol intake as wine was observed in the control group. When considered in the 
logistic regression model, a higher proportion of alcohol as wine was significantly associated 
with lower risk of cirrhosis but drinking with or between meals had no significant effect. The 
differential effect of wine, compared to other alcoholic beverages, is consistent with results of 
several previous studies (30-32) but we cannot distinguish between direct effects from some 
components of wine and confounding by other characteristics of drinkers who prefer wine. 
Nor can we be sure that we are seeing a protective effect of wine rather than a harmful effect 
associated with a preference for other beverages, because the UK Biobank data suggest that a 
higher proportion of alcohol taken as spirits is associated with higher risk of cirrhosis. It 
would be inappropriate, and potentially harmful, to infer that wine consumption is beneficial. 
Tea and coffee 
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We found replicated evidence for a protective effect of coffee consumption. In the 
GenomALC case-control comparison (Table 2) controls were more likely to have been a 
coffee drinker during the period of excessive drinking and to have drunk more coffee per day. 
In the UK Biobank data the number of cups of coffee per day was higher among the controls 
than cases (Table 4). These results are consistent with the reported protective effects of coffee 
on liver disease (14, 33), on liver function test abnormality (14, 34, 35), and (at least in 
moderate amounts) on overall mortality (36). This is the first study to demonstrate an 
independent association of coffee in subjects with well-characterised alcohol use and 
cirrhosis directly assessed for this analysis. However, there is still uncertainty about which 
components of coffee confer protection and whether it is protective after liver damage is 
already present.  
The GenomALC case-control comparison showed marginally significant protective effects of 
tea consumption when both tea and coffee were included in the multivariate analysis (Table 
3). At least among the cases, tea and coffee tended to be alternative beverages; tea drinkers 
were less likely to drink coffee and vice versa.  There were not many users of green tea 
(<10%) in our cohort, and there was only marginally significant protective effect (Table 2). In 
similar UK Biobank comparisons, coffee and tea were each significantly associated with 
lower risk and had comparable effect sizes (Table 5).  
Other substance use 
Smoking was more common among controls than cases in the GenomALC participants 
(Table 2), and the UK Biobank data confirmed this (Table 4) with current smoking being 
more frequent and never smoking being less frequent in the controls. One interpretation could 
be that smoking is protective against cirrhosis, but this is contrary to its effects on most 
diseases and cannot be accepted without other evidence. It is possible that cases had more 
contact with the healthcare system than controls and had received more intensive and 
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effective counselling about the risks of smoking, but this would not have affected the 
proportions who had never smoked. Even if smoking were protective against cirrhosis, its 
adverse impact on cardiovascular and respiratory diseases and cancers would outweigh any 
benefits. 
There has been uncertainty about whether cannabis use is protective or harmful. However, a 
recent study of over 300,000 people with a past or current history of abusive alcohol use 
showed that cannabis use was associated with lower ORs for all stages of alcohol-related 
liver disease (19). Our GenomALC data showing cannabis use was more common among the 
controls confirms this (Table 2). In addition, multivariate regression in the GenomALC 
cohort corroborated the association of cannabis as an independent protective factor for 
cirrhosis (37-39). Nevertheless many of the controls were recruited from addiction clinics and 
may have had other substance use disorders (including for cannabis) that could confound 
these results. In the UK Biobank, cannabis use had no significant effect but the proportion of 
participants with information on cannabis use was small. We observed that among 
GenomALC participants, younger patients were more likely to have used cannabis (Figure 
1(a)) but the ORs associated with reported cannabis use were consistent across age groups. 
There is independent evidence for a biological link between liver damage and cannabinoids 
and/or cannabinoid receptors (37-39), and for the therapeutic potential of several components 
of the cannabinoid system against liver cirrhosis (40).  
Obesity, diabetes and metabolic risk 
Our expectation, based on previous reports, was that obesity would be a risk factor for 
cirrhosis. This was confirmed in the GenomALC case-control comparison (Table 2), and 
when the effects of obesity and diabetes were considered together (Table 3) both were 
independently significant. Distinction between type 1 and type 2 diabetes was not specifically 
recorded in our data, but over 90% would be expected to be type 2 given the age range of our 
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study participants (41). Results in the UK Biobank were similar (Tables 4, 5) but waist/hip 
ratio showed a stronger association than BMI. Prevalence of diabetes increased with age, as 
expected (Figure 1(b)), and high-risk drinkers who have diabetes in middle age are 
particularly likely to progress to cirrhosis. The association between obesity and/or diabetes 
and risk of cirrhosis, including alcohol-related cirrhosis, has been described in community 
based cohort studies (42-44) and may reflect a similarity with non-alcoholic liver disease, 
which is related to metabolic syndrome and dysregulation of carbohydrate and lipid 
metabolism. 
Family History 
Our data show that risk of alcohol-related liver disease is transmitted in families, as we 
previously reported for a subset of our patients (24). Familial/genetic risk is well-established 
for excessive alcohol intake or alcohol dependence (21), but not for the medical 
complications of alcohol use such as cirrhosis. The transmission from fathers to offspring was 
statistically significant, with a trend for similar risk transmission from mothers (Figure 2). 
This apparent difference in risk transmission from fathers and from mothers is likely due to 
chance, to lower incidence of cirrhosis in mothers (i.e. insufficient power) and/or recall bias 
by the study participants. Transmission of risk from parents to offspring is likely to be 
genetic, given the discovery in recent years of loci associated with alcohol-related cirrhosis 
(25, 26, 45). If differential transmission of risk from fathers and mothers is a real 
phenomenon, it may be mediated through genetic/epigenetic imprinting or other mechanisms 
of selective transmission from father versus mother; multigenerational epigenetic adaptation 
to hepatic wound healing response has been elucidated in animal models (46). Confirming or 
refuting such differential transmission will require replication in other studies with family 
data, or molecular studies on epigenetic changes in candidate genes (47). 
Strengths and limitations 
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Our study design has both strengths and weaknesses. One of the issues to be addressed in 
planning a case-control study is the choice of appropriate criteria for the two groups. For the 
GenomALC cases, we restricted our recruitment to patients with alcohol-related cirrhosis and 
definition of criteria for this did not present any significant difficulty. The choice of controls 
was more complex; it is necessary to have a control group with alcohol intake which puts 
them at risk of cirrhosis and with similar lifetime alcohol exposure to the cases. In practice 
we recruited controls from clinics for treatment of substance use disorders and from 
detoxification facilities, accepting the risk that these controls might have different pattern of 
psychiatric comorbidities from the cases. In the data analysis, we sought to overcome the 
problem of non-causative differences between the GenomALC cases and controls by 
checking for consistency with results from a population-based second source of data, the UK 
Biobank. 
The recruitment of GenomALC participants in six countries is a source of strength in that it 
provides diversity and allows comparison of results (see Supplementary Table 4). In general 
the results do not differ significantly across countries, except for cannabis use and possibly 
smoking status where heterogeneity is driven by stronger effects in France. The GenomALC 
participants were mostly of European descent and the extent to which our results can be 
generalised to other populations remains to be determined. 
From the UK Biobank data, diagnoses of alcohol-related cirrhosis or alcohol-related liver 
disease were based on hospital discharge diagnoses or death certification. For the control 
group from UK Biobank, we cannot exclude liver disease and if it was present in a substantial 
proportion of these controls then power to detect effects on risk would be reduced. However, 
any such reduction in power may be mitigated by the much larger number of controls in the 
UK Biobank dataset. Reduction in power would lead to a failure to find a true difference 
Page 22 of 38 
 
between cases and controls (false negative result) rather than producing a significant but false 
difference (false positive). 
The GenomALC study was not prospective as patients were assessed after diagnosis, 
however the research questions were planned and the data collected were for the purposes of 
these analyses. The lack of prospective design is not a problem for assessment of genetic risk 
for which these patients were primarily recruited, but recall may be biased by patients’ 
knowledge of their diagnosis, and some of the postulated risk factors such as BMI may 
change as a consequence of disease. Case-control differences may be causative but could also 
be due to modes of recruitment (particularly for other drug use, including smoking). Methods 
using instrumental variables such as Mendelian Randomisation can address causation, but 
they depend on genetic association results being available for the postulated causative factors. 
Study design included definition of data and samples to be collected, but it is inevitable that 
questions will arise, often due to other research published during the course of a study, that 
were not envisaged at the outset. Although we have identified multiple risk factors for 
development of cirrhosis among high-risk drinkers, there are other factors such as variation in 
the microbiome (48), perhaps in turn associated with obesity, or infection with hepatotropic 
viruses other than B or C (49), about which we have no data.  
A further limitation, which applies to many epidemiological studies, is that associations with 
risk may not reflect cause-and-effect relationships. For all risk factors, but particularly for the 
apparent effects of smoking, cannabis use and beverage preference (wine versus spirits) 
unmeasured confounders could produce the observed associations and we caution against 
changes in these areas without further evidence. 
Conclusions 
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We identified significant associations between family history of liver disease; diabetes and 
obesity; tea, coffee, wine and cannabis consumption, and risk of cirrhosis. Our findings may 
have public health consequences if the causal relationships can be confirmed; measures such 
as weight loss, intensive treatment of diabetes or pre-diabetic states, and encouragement of 
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Table 1. Comparison of alcohol consumption in cases and controls from the GenomALC study. Results are 
shown as means ± SEM. For the log-transformed alcohol measures, grams of alcohol per day and lifetime 
alcohol consumption, the means converted back to grams or kilograms (geometric means) are shown in 
italics. 








 Male (978 cases, 555 controls) 
Controls 49.8 ± 0.41 2.333 ± 0.0010 
215 grams 
21.9 ± 0.40 3.192 ± 0.013 
1556 kg 
Cases 52.4 ± 0.28 2.282 ± 0.0095 
191 grams 
25.1 ± 0.36 3.195 ± 0.011 
1566 kg 
p-values 5.06 x 10-8 5.26 x 10-4 1.06 x 10-8 0.882 
 Female (315 cases, 199 controls) 
Controls 50.7 ± 0.72 2.239 ± 0.0167 
173 grams 
18.57 ± 0.53 3.034 ± 0.020 
1082 kg 
Cases 50.3 ± 0.52 2.160 ± 0.0016 
144 grams 
19.4 ± 0.53 2.960 ± 0.020 
912 kg 
p-values 0.603 0.0013 0.288 0.013 
 All (1293 Cases, 754 Controls) 
Controls 50.0 ± 0.36 2.308 ± 0.0085 
203 grams 
21.0 ± 0.33 3.150 ± 0.011 
1412 kg 
Cases 51.9 ± 0.25 2.252 ± 0.0084 
179 grams 
23.7 ± 0.31 3.138 ± 0.010 
1374 kg 
p-values 1.10 x 10-5 1.30 x 10-5 1.23 x 10-8 0.426 
  
Page 29 of 38 
 
Table 2. Putative risk factors compared (one at a time) in the GenomALC  cases and controls. N for the 
tested risk factors varied from 1070 to 1293 for cases and from 609 to 754 for controls. Means ± SE, or 
proportions. 
 Controls Cases p-value 
Beer, percent of total alcohol* 44.7 ± 1.58  41.7 ± 1.22  0.130 
Wine, percent of total alcohol* 37.7 ± 1.66  30.1 ± 1.18  1.76 x 10-4 
Spirits, percent of total alcohol* 35.1 ± 1.53  38.2 ± 1.22  0.124 
Other, percent of total alcohol* 5.5 ± 0.93 7.6 ± 0.78 0.101 
Usually drink with meals /  






BMI, kg/m2 25.51 ± 0.19 27.47 ± 0.16 3.55 x 10-14 
Premorbid BMI, kg/m2 24.44 ± 0.18 26.37 ± 0.15 5.77 x 10-15 
Diabetes present 48 out of 734 (6.5%) 262 out of 1280 (20.5%) 2.27 x 10-18 
Tea drinker 185 out of 751 (24.6%) 273 out of 1288 (21.2%) 0.078 
Tea, cups per day† 3.10 ± 0.23 3.07 ± 0.19 0.933 
Green Tea drinker 70 out of 749 (9.3%) 85 out of 1283 (6.6%) 0.030 
Green Tea, cups per day† 2.41 ± 0.22 2.29 ± 0.19 0.664 
Coffee drinker 502 out of 753 (66.7%) 685 out of 1290 (53.1%) 1.91 x 10-9 
Coffee, cups per day† 4.06 ± 0.19 3.46 ± 0.12 0.0053 
Smoking, Ever 624 out of 754 (82.8%) 929 out of 1293 (71.8%) 1.72 x 10-8 
Cannabis user > 5 years 200 out of 747 (26.8%) 121 out of 1287 (9.4%) 4.22 x 10-24 
* Note that although the percentages of alcohol as beer, wines, spirits or other for each person sum to 
100%, the mean percentages for cases or controls do not. When the comparison was repeated using 
the non-parametric Mann-Whitney U-test the results were similar; percentage of alcohol as wine 
differed significantly (p < 0.001) between cases and controls but percentages as beer, spirits or other 
alcoholic beverages did not (p > 0.05). 
† In participants who reported drinking tea/green tea/coffee, as appropriate.  
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Table 3. Putative risk factors compared in the GenomALC cases and controls, using multivariate logistic 
regression to identify independent effects. Sex, age, daily alcohol intake and duration of excessive drinking 
are included to adjust for any deviation from case-control matching. N = 1362 with data on all of he listed 
predictors. OR, odds ratio per unit change in predictor variable; 95% CI, 95% confidence intervals. 
 
 OR 95% CI p-value 
Variables in the equation:    
Cannabis user (0=No, 1=Yes) 0.331 0.237 – 0.464 1.18 x 10-10 
Diabetic (0=No, 1=Yes) 3.086 2.020 – 4.715 1.85 x 10-7 
Premorbid BMI, kg/m2 1.057 1.031– 1.0884 1.12 x 10-5 
Coffee drinker (0=No, 1=Yes) 0.643 0.498 – 0.830 6.87 x 10-4 
Ever smoker (0=No, 1=Yes) 0.619 0.450 – 0.853 0.0033 
Tea drinker (0=No, 1=Yes) 0.701 0.517 – 0.952 0.023 
Spirits, percent of total 1.004 1.001 – 1.007 0.019 
Duration of excessive drinking, years 1.024 1.012 – 1.036 1.39 x 10-4 
Variables not in the equation:    
Sex   0.438 
Age, years   0.944 
Alcohol intake, grams/day   0.223 
BMI, kg/m2   0.122 
Wine, percent of total   0.549 
Drink with meals?   0.413 
Green tea drinker (0=No, 1=Yes)   0.897 
Beer, percent of total   0.447 
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Table 4. Putative risk factors compared (one at a time) in the UK Biobank participants. 
Means ± SE and N, or proportions. 
 
 Controls Cases p-value 
BMI, kg/m2 28.05 ± 0.06 (6534) 28.87 ± 0.27 (401) 6.51 x 10-4 
Waist/Hip Ratio 0.931 ± 0.001 (6550) 0.969 ± 0.004 (403) 7.67 x 10-20 
Diabetes present 353 out of 6573 (5.4%) 122 out of 407 (30.0%) 4.05 x 10-50 
Red or white wine, percent of total 
alcohol 
32.3 ± 0.44% (6515) 25.9 ± 2.12% (251) 0.0049 
Beer or cider, percent of total alcohol 58.4 ± 0.47% (6525) 57.4 ± 2.53% (253) 0.679 
Spirits, percent of total alcohol 8.4 ± 0.23% (6526) 15.4 ± 1.72% (254) 9.65 x 10-9 
Tea, cups per day 3.24 ± 0.04 (6298) 3.13 ± 0.18 (382) 0.512 
Coffee, cups per day 2.18 ± 0.03 (6064) 1.91 ± 0.12 (366) 0.026 
Smoking, Ever 4895 out of 6557 (74.7%) 283 out of 404 (70.0%) 0.046 
Cannabis (ordinal measure of number 
of occasions) 
0.930 ± 0.034 (1518) 0.871 ± 0.211 (31) 0.805 
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Table 5. Putative risk factors compared in the UK Biobank cases and controls. Multivariate logistic 
regression with stepwise inclusion of potential predictors of case-control status, to identify independent and 
significant effects. Sex and age are included to adjust for any deviation from case-control matching. OR, 
odds ratio per unit change in predictor variable; 95% CI, 95% confidence intervals. Note that cannabis 
information is not included as a potential predictor because it would reduce the available numbers too 
greatly. 
 
 OR 95% CI p-value 
Variables in the equation:    
Diabetic (0=No, 1=Yes) 6.25 4.41 – 8.86 6.21 x 10-25 
Waist/Hip Ratio (WHR x 100) 1.062 1.040 – 1.084 2.28 x 10-8 
Spirits, percent of total alcohol 1.011 1.006 - 1.017 8.51 x 10-5 
Body mass index, kg/m2 0.940 0.908 – 0.974 5.90 x 10-4 
Tea (cups per day) 0.928 0.877 - 0.981 0.0088 
Coffee (cups per day) 0.915 0.851 - 0.984 0.017 
Variables not in the equation:    
Sex   0.088 
Smoking (Ever)   0.156 
Age, years   0.589 
Red or white wine, percent of total alcohol   0.681 
Beer or cider, percent of total alcohol   0.834 
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LEGENDS TO FIGURES 
 
Figure 1. Prevalence and Odds Ratios (ORs) by age group for (a) reported cannabis use, (b) 
diabetes, in GenomALC cases and controls. For cannabis use, Odds Ratios did not show 
significant heterogeneity between age groups (p = 0.200) but for diabetes Odds Ratios 
showed significant heterogeneity between age groups (p = 0.0044). 
 
Figure 2. Odds ratios for alcoholic cirrhosis in male and female GenomALC participants, by 
reported parental death from liver disease (if the parent was reported to have had alcohol 
problems). 
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Supplementary Table 1. Number of cases with cirrhosis-related symptoms or events. 
Reported occurrence at any time; note that patients may have experienced more than one of 
these. 
 
 N % 
Total Cases 1293 100 
   
Ascites 980 75.8 
Oesophageal varices 410 31.7 
Encephalopathy 663 51.3 
Hepatocellular carcinoma 147 11.4 
Liver transplant 145 11.2 
 
 
Supplementary Table 2. Case and control numbers by sex and country of recruitment. 
 
 
 Australia France Germany Switzerland UK USA 
 CASE CONTROL CASE CONTROL CASE CONTROL CASE CONTROL CASE CONTROL CASE CONTROL 
Female 30 60 107 25 30 41 5 13 88 38 55 22 
Male 117 155 332 112 51 128 26 28 234 78 218 54 
             




Supplementary Table 3. Alcohol consumption in cases and controls from the UK Biobank. Cases = 
alcohol-related cirrhosis, controls = reported alcohol intake 80 g/day or more for men, 50 g/day or more for 
women, similar or greater alcohol intake 10 years previously, with no reported alcohol-related liver disease. 
Means ± SEM. For the log-transformed alcohol measure, grams of alcohol per day, the means converted 
back to grams or kilograms (geometric means) are shown in italics. 
 
 Males Females 









Controls: alcohol intake 
80M/50F g/day or more 
 
56.5 ± 0.11 2.012 ± 0.0014 
103 grams 
 
54.8 ± 0.20 1.816 ± 0.0026 
66 grams 
 
Cases: alcoholic cirrhosis 58.1 ± 0.37 1.122 ± 0.048 
13 grams 
 
58.1 ± 0.88 0.860 ± 0.089 
7 grams 
 




Supplementary Table 4. Comparison of associations with Case-Control status by country of patient recruitment. 
 
 
Odds Ratios for binary variables 
 Cannabis Diabetes Coffee Tea Ever Smoker 
 OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
Australia 0.235 0.134 - 0.414 1.53E-07 5.726 2.864 - 11.451 1.82E-07 0.361 0.234 - 0.556 4.00E-06 1.011 0.653 - 1.564 1.000 0.405 0.251 - 0.656 2.33E-04 
France 0.094 0.052 - 0.171 2.52E-16 4.963 2.242 - 10.987 4.00E-06 0.723 0.469 - 1.115 0.167 1.670 0.628 - 4.436 0.388 0.193 0.082 - 0.453 7.00E-06 
Germany 0.339 0.096 - 1.193 0.087 4.400 1.925 - 10.058 4.24E-04 0.458 0.264 - 0.795 0.0065 0.760 0.384 - 1.507 0.501 0.849 0.445 - 1.622 0.619 
Switzerland 0.864 0.222 - 3.371 1.000 2.040 0.520 - 8.000 0.494 0.264 0.073 - 0.961 0.061 2.436 0.535 - 11.091 0.278 1.636 0.444 - 6.026 0.536 
UK 0.252 0.137 - 0.461 1.00E-05 2.423 1.195 - 4.913 0.012 0.622 0.405 - 0.956 0.037 0.913 0.595 - 1.402 0.742 0.438 0.259 - 0.741 0.0019 
USA 0.458 0.263 - 0.798 0.0088 2.966 1.136 - 7.745 0.018 0.711 0.426 - 1.189 0.198 0.856 0.433 - 1.696 0.720 0.739 0.425 - 1.287 0.339 
                
Heterogeneity p   0.0017   0.471   0.147   0.635   0.015 
Common OR 0.251 0.191 - 0.330  3.795 2.697 - 5.340  0.547 0.446 - 0.671  0.980 0.767 - 1.251  0.493 0.385 - 0.631  
Overall p-value   3.37E-23   1.94E-14   7.71E-09   0.871   1.98E-08 
 
 
Odds Ratios from logistic regression for continuous variables 
 Wine percent Drink with meals (ordinal*) BMI Pre-morbid BMI 
 OR CI95 p OR CI95 p OR CI95 p OR CI95 p 
Australia 0.995 0.989 - 1.001 0.083 2.153 1.106 - 4.191 0.024 1.067 1.023 - 1.111 0.0022 1.100 1.054 - 1.149 1.48E-05 
France 1.002 0.996 - 1.007 0.555 2.025 1.084 - 3.784 0.027 1.083 1.038 - 1.129 2.00E-04 1.079 1.031 - 1.129 9.79E-04 
Germany 1.013 1.006 - 1.020 0.001 4.814 1.404 - 16.507 0.012 1.063 1.005 - 1.124 0.034 1.031 0.968 - 1.097 0.342 
Switzerland 1.001 0.988 - 1.014 0.869 1.769 0.258 - 12.105 0.561 1.175 1.049 - 1.315 0.0051 1.153 1.015 - 1.310 0.028 
UK 1.005 0.998 - 1.011 0.167 0.986 0.435 - 2.234 0.972 1.101 1.051 - 1.153 5.10E-05 1.074 1.027 - 1.125 0.0020 
USA 0.999 0.986 - 1.012 0.863 0.767 0.310 - 1.895 0.565 1.000 0.957 - 1.045 0.998 1.032 0.985 - 1.080 0.189 
             
All 0.995 0.993 - 0.998 1.74E-04 1.576 1.153 - 2.153 0.0043 1.071 1.052 - 1.091 1.44E-13 1.078 1.057 - 1.099 2.72E-14 
 
*The ‘Drink with meals’ variable was recoded as ‘Mostly drink with meals’ = 1, ‘Mostly drink between meals’ = 0, ‘Both’ = 0.5.
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AJG-20-0154. FACTORS THAT ALTER RISK FOR ALCOHOL-RELATED 
CIRRHOSIS IN HIGH-RISK DRINKERS 
 




We thank the editors and reviewers for their comments, and appreciate the opportunity 
to submit a revised version of this paper. 
 
In the text below, the editors’ or reviewers’ comments are in italics and our responses 
are indented below each comment. Page numbers, where mentioned below, refer to the 
revision. 
 
Editor/Editorial Board Comments: 
 
The editorial board asks the authors to address the following points: 
   
1. Adjust for duration of alcohol use, and not only for accumulated quantity of alcohol 
consumed. 
 
We assume the concern arises from the difference in years of drinking 
between cases and controls in the GenomALC cohort, and the possibility 
that duration of alcohol use might have effects independent of lifetime 
quantity.  
 
We have re-run the logistic regression in Table 3 with additional 
independent variables. These are sex, age, alcohol intake in grams/day, 
duration of excessive alcohol use, but not lifetime quantity because this is 
the product of quantity and duration. Duration of excessive alcohol use is 
significant (consistent with the results in Table 1). This makes little 
difference to the HR estimates and p-values for the other variables, but we 
have changed Table 3 and its legend to reflect the duration-of-alcohol-use 
effect. 
 
For consistency, we also repeated the logistic regression for UK Biobank 
data with addition of sex, and age at assessment. It was not appropriate to 
include alcohol intake (grams/day) because we only have data on 
consumption at the time of assessment and this is low in the cases 
(Supplementary Table 3) because many participants declared that they had 
reduced their intake compared to 10 years previously; and it was not 
possible to include duration of excessive intake because this was not 
available. This made no difference to HR estimates for the other variables, 
but we have changed Table 5 and its legend to be as consistent as possible 
with Table 3. 
 
2. Revise title to make it more clear what the protective effects were in this study. 
 
We have done this, by changing from ‘Factors that alter risk for alcohol-
related cirrhosis in high-risk drinkers’ to ‘Obesity, diabetes, coffee, tea and 
Author Response to Reviewers
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cannabis use alter risk for alcohol-related cirrhosis in two large cohorts of 
high-risk drinkers’. 
 
3. Discuss the possible effects of the microbiome on ALD in individuals at risk due to 
heavy alcohol use. 
 
We have no data or relevant samples to allow us to do more than mention 
this in the Discussion. We have expanded the section discussing the 
strengths and limitations of our study by noting that there are potential risk 
factors which we did not include in our protocol and cannot provide 
evidence about. These include the microbiome (Bajaj JS, Nat Rev 
Gastroenterol Hepatol 2019;16 235-246) and no doubt other factors. 
 
4. Make clear to the readers that the data is NOT about promoting wine over other alcoholic 
beverages when it comes to ALD. 
 
We agree that the associations between beverage preference and cirrhosis 
risk do not necessarily mean there is a causal relationship. There are many 
potential confounders, and we have now given additional emphasis to this 
in the Discussion (pages 17 and 22). 
 
5. Provide a country-wise comparison of the GenomALC data. 
 
We have given information about variation in recruitment, and possible 
heterogeneity of results, between countries in Supplementary Tables 2 and 4 and 
Supplementary Figure 1 of the original submission. These give the numbers of 
cases and controls by country, lifetime alcohol intake by country, and test for 
heterogeneity of effect sizes by country. We have added a comment to the 
Discussion about possible differences between countries on page 21.  
 
6. Recognize the limitations of the data analysis regarding the lack of information on non-
cirrhotic ALD among the control groups. Even though these heavy drinkers didn't develop 
cirrhosis (as defined by the authors), they could still have developed other forms of ALD or 
certainly have had other alcohol-related illnesses that were not captured in this study. 
 
At least for the GenomALC participants, we are comfortable that controls 
did not have non-cirrhotic ALD, had not had it in the past, and (because 
they were matched for age with the cases) had reached an age and lifetime 
alcohol exposure where they would probably have had it if they were 
going to. Even if some controls did have undetected ALD (which is more 
likely for the UKB participants), this would minimise the difference 
between cases and controls and reduce power rather than producing an 
apparently significant but untrue difference. A comment to this effect has 
been added to the Discussion (pages 21-22). 
 
 
Reviewer #1: Comments to the Authors: 
 
The authors investigated a multi-center case-control study comparing 1293 cases and 
754 controls. The authors identified significant associations between family history of 
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liver disease; diabetes and obesity; tea, coffee, wine and cannabis consumption, and risk 
of cirrhosis. It is an interesting study though, there are some issues that need to be 
clarified. 
 
1) Some people say that "pure non-alcoholic steatohepatitis "patients are very limited 
population as most of so-called NASH patients have some history of alcohol consumption and 
its amount is not enough to be diagnosed as Alcoholic steatohepatitis. The authors' data 
mention that cases had a higher prevalence of diabetes and pre-morbid BMI than controls. 
Since these parameters are considered as metabolic factors, I would like to know the data of 
lipid metabolism and hypertension in both groups. 
 
We accept that the boundaries between NASH and alcohol-related cirrhosis may 
be blurred and that risk can be additive or worse across these causes. As far as 
lipids and hypertension go, we only have data on lipids from the time of 
recruitment and this most likely reflects changes caused by liver disease rather 
than reflecting lipid-related risk. The same applies to prevalence of hypertension 
or to mean blood pressure. Future work incorporating genetic information (risk 
scores for lipids or blood pressure) may allow testing for such effects but that is 
beyond the scope of this paper. 
 
2) Was hepatitis E checked in both cases and controls? This is because hepatitis E 
infection is more frequent in cirrhotic patients and this may cause additional liver 
dysfunction. 
 
We did not gather data on hepatitis E so we cannot address this directly. We 
note the recent report of a high proportion of patients with alcohol-related 
cirrhosis being seropositive for hepatitis E (Fantilli et al. Unexpected high 
seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis. 
PLoS One. 2019 Oct 24;14(10):e0224404), and we cannot exclude the 
possibility that previous hepatitis E infection may increase the probability of 
cirrhosis among excessive drinkers. This is now mentioned in the Discussion 
(page 22). 
. 
3) I would like to know if there is any difference regarding the incidence of satellitosis 
(neutrophil infiltration confirmed by liver biopsy) in both groups. 
 
Biopsies had only been carried out in patients for whom this had been 
considered clinically necessary (30% of cases and 1% of controls) and we did 
not collect detailed information on the liver biopsy appearances. Therefore we 




Reviewer #2:  
 
Thank you to the authors for their work. Two questions come to mind: 
 
1. The GenomALC data includes population from the UK. In your paper the population 
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from the UK was not extracted from the GenomALC data and the numbers are not 
available for a proper comparison and for an unskewed and unbiased result 
 
We understand the potential issue to be double counting, as some of the 
UK participants might have been in both the GenomALC and UKB 
groups. We have done some simple calculations to address this. 
  
UKB recruited 0.5m people aged 40-69 in 2006-2010. The population of 
the UK in this age group a few years later in 2018  was 24.5m (see 
https://www.statista.com/statistics/281174/uk-population-by-age/) so UKB 
recruited approximately one-fiftieth, 2% of the eligible people. This 
implies that 2% of the GenomALC UK participants might also have been 
in UKB. An additional consideration is that people cannot be in UKB 
unless they were over 40 in 2010 (born before the end of 1970). The 
GenomALC UK component contained 438 participants, 363 born in or 
before 1970, so the number who might also be in the UKB is 2% of 363 or 
7. This is 0.34% of the total GenomALC cohort and we consider this is not 
enough to make a practical difference to our results. 
 
2. Results of the study do not differ from the paper by Whitfield (Genom ALC study), 
neither did the weaknesses that you also mention in your study. As I expected, the 
reader may also expect to see a novel idea such as a prospective follow up to the 
Genom Alc report that includes for example liver biopsies , genetic analysis etc. 
 
The work described in this paper describes novel analyses derived from 
data on the GenomALC cohort which have not previously been reported. 
These analyses form part of our pre-planned program as described in our 
earlier paper (Whitfield et al. Brief Report: Genetics of Alcoholic 
Cirrhosis — GenomALC Multinational Study. Alcoholism: Clinical and 
Experimental Research 2015;39:836-842). Novel aspects of the current 
paper include results for clinical and behavioural risk factors such as 
obesity, diabetes and substance use, and extension of our data to include 
the UK Biobank to validate and reinforce our conclusions. Other aspects 
including a genome-wide association study will be published as separate 
papers. 
 
 
